MIF, CD74 and other partners in kidney disease: Tales of a promiscuous couple

Cytokine and Growth Factor Reviews

Volumn 24, Issue 1, 2013, Pages 23-40

  Sanchez Nino M D ^a   Sanz, A B ^a   Ruiz Andres, O ^b   Poveda, J ^b   Izquierdo, M C ^b   Selgas, R ^a,e   Egido, J ^b,c,d,f   Ortiz, A ^b,c,d  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b Instituto de Investigación Sanitaria Fundación Jiménez Díaz   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Section of Nephrology   (Spain)

^e IdiPAZ ^*  (Spain)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

CD74; CXCR2; CXCR4; Kidney; Macrophage inhibitory factor

Indexed keywords

3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID METHYL ESTER; BACTERIAL PROTEIN; CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CORTICOTROPIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOPACHROME TAUTOMERASE; EBSELEN; HERMES ANTIGEN; IBUDILAST; ISO 1; ISOXAZOLE DERIVATIVE; MACROPHAGE MIGRATION INHIBITION FACTOR; MILATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLERIXAFOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

B CELL LEUKEMIA; B CELL LYMPHOMA; CELL SURFACE; CHRONIC KIDNEY DISEASE; CONGENITAL NEPHROTIC SYNDROME; CYTOKINE RELEASE; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOTOXEMIA; FOCAL GLOMERULOSCLEROSIS; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOREGULATION; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHROTOXICITY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; URIC ACID NEPHROPATHY;

BACTERIA (MICROORGANISMS);

EID: 84874261968     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.08.001     Document Type: Review

References (234)

1. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proceedings of the National Academy of Sciences United States of America 1966, 56:72-77.
2. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993, 365:756-759.
3. Mitchell R., Bacher M., Bernhagen J., Pushkarskaya T., Seldin M.F., Bucala R. Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). Journal of Immunology 1995, 154:3863-3870.
4. Donn R.P., Ray D.W. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. Journal of Endocrinology 2004, 182:1-9.
5. Bendrat K., Al-Abed Y., Callaway D.J., Peng T., Calandra T., Metz C.N., et al. Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry 1997, 36:15356-15362.
6. El-Turk F., Cascella M., Ouertatani-Sakouhi H., Narayanan R.L., Leng L., Bucala R., et al. The conformational flexibility of the carboxy terminal residues 105-114 is a key modulator of the catalytic activity and stability of macrophage migration inhibitory factor. Biochemistry 2008, 47:10740-10756.
7. Kleemann R., Kapurniotu A., Frank R.W., Gessner A., Mischke R., Flieger O., et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. Journal of Molecular Biology 1998, 280:85-102.
8. Weber C., Kraemer S., Drechsler M., Lue H., Koenen R.R., Kapurniotu A., et al. Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proceedings of the National Academy of Sciences United States of America 2008, 105:16278-16283.
9. Kraemer S., Lue H., Zernecke A., Kapurniotu A., Andreetto E., Frank R., et al. MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. FASEB Journal 2011, 25:894-906.
10. Kleemann R., Hausser A., Geiger G., Mischke R., Burger-Kentischer A., Flieger O., et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000, 408:211-216.
11. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nature Medicine 2007, 13:587-596.
12. Mitchell R.A., Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Seminars in Cancer Biology 2000, 10:359-366.
13. Morand E.F., Bucala R., Leech M. Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis. Arthritis & Rheumatism 2003, 48:291-299.
14. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proceedings of the National Academy of Sciences United States of America 1996, 93:7849-7854.
15. Metz C.N., Bucala R. Role of macrophage migration inhibitory factor in the regulation of the immune response. Advances in Immunology 1997, 66:197-223.
16. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71.
17. Denkinger C.M., Metz C., Fingerle-Rowson G., Denkinger M.D., Forsthuber T. Macrophage migration inhibitory factor and its role in autoimmune diseases. Archivum Immunologiae et Therapiae Experimentalis (Warsz) 2004, 52:389-400.
18. Toso C., Emamaullee J.A., Merani S., Shapiro A.M. The role of macrophage migration inhibitory factor on glucose metabolism and diabetes. Diabetologia 2008, 51:1937-1946.
19. Harper J.M., Wilkinson J.E., Miller R.A. Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction. FASEB Journal 2010, 24:2436-2442.
20. Schober A., Bernhagen J., Weber C. Chemokine-like functions of MIF in atherosclerosis. Journal of Molecular Medicine (Berlin) 2008, 86:761-770.
21. Bernhagen J., Bacher M., Calandra T., Metz C.N., Doty S.B., Donnelly T., et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. Journal of Experimental Medicine 1996, 183:277-282.
22. Donnelly S.C., Haslett C., Reid P.T., Grant I.S., Wallace W.A., Metz C.N., et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Medicine 1997, 3:320-323.
23. Pan J.H., Lindholt J.S., Sukhova G.K., Baugh J.A., Henneberg E.W., Bucala R., et al. Macrophage migration inhibitory factor is associated with aneurysmal expansion. Journal of Vascular Surgery 2003, 37:628-635.
24. Meyer-Siegler K.L., Vera P.L., Iczkowski K.A., Bifulco C., Lee A., Gregersen P.K., et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes & Immunity 2007, 8:646-652.
25. Leng L., Metz C.N., Fang Y., Xu J., Donnelly S., Baugh J., et al. MIF signal transduction initiated by binding to CD74. Journal of Experimental Medicine 2003, 197:1467-1476.
26. Starlets D., Gore Y., Binsky I., Haran M., Harpaz N., Shvidel L., et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006, 107:4807-4816.
27. Leech M., Metz C., Hall P., Hutchinson P., Gianis K., Smith M., et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis & Rheumatism 1999, 42:1601-1608.
28. Liu Y.H., Lin C.Y., Lin W.C., Tang S.W., Lai M.K., Lin J.Y. Up-regulation of vascular endothelial growth factor-D expression in clear cell renal cell carcinoma by CD74: a critical role in cancer cell tumorigenesis. Journal of Immunology 2008, 181:6584-6594.
29. Gregory J.L., Leech M.T., David J.R., Yang Y.H., Dacumos A., Hickey M.J. Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis & Rheumatism 2004, 50:3023-3034.
30. Simons D., Grieb G., Hristov M., Pallua N., Weber C., Bernhagen J., et al. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. Journal of Cellular and Molecular Medicine 2011, 15:668-678.
31. Bach J.P., Rinn B., Meyer B., Dodel R., Bacher M. Role of MIF in inflammation and tumorigenesis. Oncology 2008, 75:127-133.
32. Calandra T., Echtenacher B., Roy D.L., Pugin J., Metz C.N., Hultner L., et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Medicine 2000, 6:164-170.
33. Mikulowska A., Metz C.N., Bucala R., Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. Journal of Immunology 1997, 158:5514-5517.
34. Leech M., Hutchinson P., Holdsworth S.R., Morand E.F. Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis. Clinical & Experimental Immunology 1998, 112:383-388.
35. Santos L., Hall P., Metz C., Bucala R., Morand E.F. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clinical & Experimental Immunology 2001, 123:309-314.
36. Daun J.M., Cannon J.G. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IkappaBalpha. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2000, 279:R1043-R1049.
37. Roger T., Chanson A.L., Knaup-Reymond M., Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. European Journal of Immunology 2005, 35:3405-3413.
38. Nguyen M.T., Beck J., Lue H., Funfzig H., Kleemann R., Koolwijk P., et al. A 16-residue peptide fragment of macrophage migration inhibitory factor, MIF-(50-65), exhibits redox activity and has MIF-like biological functions. Journal of Biological Chemistry 2003, 278:33654-33671.
39. Sanchez-Zamora Y., Terrazas L.I., Vilches-Flores A., Leal E., Juarez I., Whitacre C., et al. Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB Journal 2010, 24:2583-2590.
40. Denz A., Pilarsky C., Muth D., Ruckert F., Saeger H.D., Grutzmann R. Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. Journal of Surgical Research 2010, 160:29-34.
41. Wu M.Y., Fu J., Xu J., O'Malley B.W., Wu R.C. Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor. Cell Research 2012, 22:1003-1021.
42. Meyer-Siegler K.L., Iczkowski K.A., Leng L., Bucala R., Vera P.L. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. Journal of Immunology 2006, 177:8730-8739.
43. Baumann R., Casaulta C., Simon D., Conus S., Yousefi S., Simon H.U. Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway. FASEB Journal 2003, 17:2221-2230.
44. Damico R.L., Chesley A., Johnston L., Bind E.P., Amaro E., Nijmeh J., et al. Macrophage migration inhibitory factor governs endothelial cell sensitivity to LPS-induced apoptosis. American Journal of Respiratory Cell and Molecular Biology 2008, 39:77-85.
45. Kim J.Y., Kwok S.K., Hur K.H., Kim H.J., Kim N.S., Yoo S.A., et al. Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis. Clinical & Experimental Immunology 2008, 152:328-335.
46. Lue H., Thiele M., Franz J., Dahl E., Speckgens S., Leng L., et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007, 26:5046-5059.
47. Jung H., Seong H.A., Ha H. Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. Journal of Biological Chemistry 2008, 283:20383-20396.
48. Liu L., Chen J., Ji C., Zhang J., Sun J., Li Y., et al. Macrophage migration inhibitory factor (MIF) interacts with Bim and inhibits Bim-mediated apoptosis. Molecules & Cells 2008, 26:193-199.
49. Honda A., Abe R., Yoshihisa Y., Makino T., Matsunaga K., Nishihira J., et al. Deficient deletion of apoptotic cells by macrophage migration inhibitory factor (MIF) overexpression accelerates photocarcinogenesis. Carcinogenesis 2009, 30:1597-1605.
50. Chuang Y.C., Su W.H., Lei H.Y., Lin Y.S., Liu H.S., Chang C.P., et al. Macrophage migration inhibitory factor induces autophagy via reactive oxygen species generation. PLoS One 2012, 7:e37613.
51. Dhanantwari P., Nadaraj S., Kenessey A., Chowdhury D., Al-Abed Y., Miller E.J., et al. Macrophage migration inhibitory factor induces cardiomyocyte apoptosis. Biochemical and Biophysical Research Communications 2008, 371:298-303.
52. Inacio A.R., Ruscher K., Leng L., Bucala R., Deierborg T. Macrophage migration inhibitory factor promotes cell death and aggravates neurologic deficits after experimental stroke. Journal of Cerebral Blood Flow & Metabolism 2011, 31:1093-1106.
53. Heinrichs D., Knauel M., Offermanns C., Berres M.L., Nellen A., Leng L., et al. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proceedings of the National Academy of Sciences United States of America 2011, 108:17444-17449.
54. Taylor J.A., Zhu Q., Irwin B., Maghaydah Y., Tsimikas J., Pilbeam C., et al. Null mutation in macrophage migration inhibitory factor prevents muscle cell loss and fibrosis in partial bladder outlet obstruction. American Journal of Physiology-Renal Physiology 2006, 291:F1343-F1353.
55. Shan Z.X., Lin Q.X., Yang M., Zhang B., Zhu J.N., Mai L.P., et al. Transcription factor Ap-1 mediates proangiogenic MIF expression in human endothelial cells exposed to Angiotensin II. Cytokine 2011, 53:35-41.
56. Kim H.R., Park M.K., Cho M.L., Yoon C.H., Lee S.H., Park S.H., et al. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. Journal of Rheumatology 2007, 34:927-936.
57. Hira E., Ono T., Dhar D.K., El-Assal O.N., Hishikawa Y., Yamanoi A., et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005, 103:588-598.
58. Xu X., Wang B., Ye C., Yao C., Lin Y., Huang X., et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Letters 2008, 261:147-157.
59. Liao B., Zhong B.L., Li Z., Tian X.Y., Li Y., Li B. Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma. Journal of Surgical Oncology 2010, 102:844-851.
60. Veillat V., Carli C., Metz C.N., Al-Abed Y., Naccache P.H., Akoum A. Macrophage migration inhibitory factor elicits an angiogenic phenotype in human ectopic endometrial cells and triggers the production of major angiogenic factors via CD44, CD74, and MAPK signaling pathways. Journal of Clinical Endocrinology & Metabolism 2010, 95:E403-E412.
61. Schwartz V., Kruttgen A., Weis J., Weber C., Ostendorf T., Lue H., et al. Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF. European Journal of Cell Biology 2012, 91:435-449.
62. Kleemann R., Grell M., Mischke R., Zimmermann G., Bernhagen J. Receptor binding and cellular uptake studies of macrophage migration inhibitory factor (MIF): use of biologically active labeled MIF derivatives. Journal of Interferon & Cytokine Research 2002, 22:351-363.
63. Nemajerova A., Mena P., Fingerle-Rowson G., Moll U.M., Petrenko O. Impaired DNA damage checkpoint response in MIF-deficient mice. EMBO Journal 2007, 26:987-997.
64. Lue H., Kapurniotu A., Fingerle-Rowson G., Roger T., Leng L., Thiele M., et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signaling 2006, 18:688-703.
65. Sasaki S., Nishihira J., Ishibashi T., Yamasaki Y., Obikane K., Echigoya M., et al. Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney International 2004, 65:469-481.
66. Tesch G.H., Nikolic-Paterson D.J., Metz C.N., Mu W., Bacher M., Bucala R., et al. Rat mesangial cells express macrophage migration inhibitory factor in vitro and in vivo. Journal of the American Society of Nephrology 1998, 9:417-424.
67. Leung J.C., Chan L.Y., Tsang A.W., Liu E.W., Lam M.F., Tang S.C., et al. Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy. Nephrology Dialysis Transplantation 2004, 19:1976-1985.
68. Sanchez-Nino M.D., Sanz A.B., Ihalmo P., Lassila M., Holthofer H., Mezzano S., et al. The MIF receptor CD74 in diabetic podocyte injury. Journal of the American Society of Nephrology 2009, 20:353-362.
69. Huber T.B., Reinhardt H.C., Exner M., Burger J.A., Kerjaschki D., Saleem M.A., et al. Expression of functional CCR and CXCR chemokine receptors in podocytes. Journal of Immunology 2002, 168:6244-6252.
70. Aeberli D., Yang Y., Mansell A., Santos L., Leech M., Morand E.F. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Letters 2006, 580:974-981.
71. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nature Reviews Immunology 2003, 3:791-800.
72. Bacher M., Meinhardt A., Lan H.Y., Dhabhar F.S., Mu W., Metz C.N., et al. MIF expression in the rat brain: implications for neuronal function. Molecular Medicine 1998, 4:217-230.
73. Bernhagen J., Calandra T., Cerami A., Bucala R. Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. Trends in Microbiology 1994, 2:198-201.
74. Nishio Y., Minami A., Kato H., Kaneda K., Nishihira J. Identification of macrophage migration inhibitory factor (MIF) in rat peripheral nerves: its possible involvement in nerve regeneration. Biochimica et Biophysica Acta 1999, 1453:74-82.
75. Wada S., Fujimoto S., Mizue Y., Nishihira J. Macrophage migration inhibitory factor in the human ovary: presence in the follicular fluids and production by granulosa cells. Biochemistry & Molecular Biology International 1997, 41:805-814.
76. Meinhardt A., Bacher M., McFarlane J.R., Metz C.N., Seitz J., Hedger M.P., et al. Macrophage migration inhibitory factor production by Leydig cells: evidence for a role in the regulation of testicular function. Endocrinology 1996, 137:5090-5095.
77. Wistow G.J., Shaughnessy M.P., Lee D.C., Hodin J., Zelenka P.S. A macrophage migration inhibitory factor is expressed in the differentiating cells of the eye lens. Proceedings of the National Academy of Sciences United States of America 1993, 90:1272-1275.
78. Waeber G., Calandra T., Roduit R., Haefliger J.A., Bonny C., Thompson N., et al. Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proceedings of the National Academy of Sciences United States of America 1997, 94:4782-4787.
79. Merk M., Zierow S., Leng L., Das R., Du X., Schulte W., et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proceedings of the National Academy of Sciences United States of America 2011, 108:E577-E585.
80. Merk M., Baugh J., Zierow S., Leng L., Pal U., Lee S.J., et al. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. Journal of Immunology 2009, 182:6896-6906.
81. Merk M., Mitchell R.A., Endres S., Bucala R. D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine 2012, 59:10-17.
82. Schulz R., Marchenko N.D., Holembowski L., Fingerle-Rowson G., Pesic M., Zender L., et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. Journal of Experimental Medicine 2012, 209:275-289.
83. Isidori A.M., Kaltsas G.A., Korbonits M., Pyle M., Gueorguiev M., Meinhardt A., et al. Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease. Journal of Clinical Endocrinology & Metabolism 2002, 87:1834-1840.
84. Bomback A.S., Tumlin J.A., Baranski J., Bourdeau J.E., Besarab A., Appel A.S., et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Design, Development and Therapy 2011, 5:147-153.
85. Lan H.Y., Mu W., Yang N., Meinhardt A., Nikolic-Paterson D.J., Ng Y.Y., et al. De Novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. American Journal of Pathology 1996, 149:1119-1127.
86. Lan H.Y., Yang N., Nikolic-Paterson D.J., Yu X.Q., Mu W., Isbel N.M., et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney International 2000, 57:499-509.
87. Imamura K., Nishihira J., Suzuki M., Yasuda K., Sasaki S., Kusunoki Y., et al. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney. Biochemistry & Molecular Biology International 1996, 40:1233-1242.
88. Lan H.Y., Yang N., Brown F.G., Isbel N.M., Nikolic-Paterson D.J., Mu W., et al. Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation 1998, 66:1465-1471.
89. Leung J.C., Tang S.C., Chan L.Y., Tsang A.W., Lan H.Y., Lai K.N. Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrology Dialysis Transplantation 2003, 18:36-45.
90. Chan L.Y., Leung J.C., Tsang A.W., Tang S.C., Lai K.N. Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney International 2005, 67:602-612.
91. Lan H.Y., Bacher M., Yang N., Mu W., Nikolic-Paterson D.J., Metz C., et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. Journal of Experimental Medicine 1997, 185:1455-1465.
92. Rice E.K., Nikolic-Paterson D.J., Hill P.A., Metz C.N., Bucala R., Atkins R.C., et al. Interferon-gamma induces macrophage migration inhibitory factor synthesis and secretion by tubular epithelial cells. Nephrology (Carlton) 2003, 8:156-161.
93. Rice E.K., Tesch G.H., Cao Z., Cooper M.E., Metz C.N., Bucala R., et al. Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II. Kidney International 2003, 63:1265-1275.
94. Huang Z., Wen Q., Zhou S.F., Yu X.Q. Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome. Cytokine 2008, 42:222-233.
95. Santini E., Lupi R., Baldi S., Madec S., Chimenti D., Ferrannini E., et al. Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabetologia 2008, 51:2117-2125.
96. Yu X.Y., Chen H.M., Liang J.L., Lin Q.X., Tan H.H., Fu Y.H., et al. Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor. PLoS One 2011, 6:e16239.
97. Liang J.L., Xiao D.Z., Liu X.Y., Lin Q.X., Shan Z.X., Zhu J.N., et al. High glucose induces apoptosis in AC16 human cardiomyocytes via macrophage migration inhibitory factor and c-Jun N-terminal kinase. Clinical and Experimental Pharmacology and Physiology 2010, 37:969-973.
98. Bucala R. MIF and the genetic basis of macrophage responsiveness. Current Immunology Reviews 2006, 2:217-223.
99. Plant B.J., Gallagher C.G., Bucala R., Baugh J.A., Chappell S., Morgan L., et al. Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism. American Journal of Respiratory and Critical Care Medicine 2005, 172:1412-1415.
100. Plant B.J., Ghani S., O'Mahony M.J., Morgan L., O'Connor C.M., Morgan K., et al. Sarcoidosis and MIF gene polymorphism: a case-control study in an Irish population. European Respiratory Journal 2007, 29:325-329.
101. Mizue Y., Ghani S., Leng L., McDonald C., Kong P., Baugh J., et al. Role for macrophage migration inhibitory factor in asthma. Proceedings of the National Academy of Sciences United States of America 2005, 102:14410-14415.
102. Baugh J.A., Chitnis S., Donnelly S.C., Monteiro J., Lin X., Plant B.J., et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes & Immunity 2002, 3:170-176.
103. Sreih A., Ezzeddine R., Leng L., LaChance A., Yu G., Mizue Y., et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis & Rheumatism 2011, 63:3942-3951.
104. Renner P., Roger T., Bochud P.Y., Sprong T., Sweep F.C., Bochud M., et al. A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB Journal 2012, 26:907-916.
105. Sakagami K. Early prediction of acute rejection after inbred rat kidney transplantation using macrophage migration inhibition test. Acta Medica Okayama 1976, 30:181-195.
106. Orita K., Sakagami K., Fuchimoto S., Arima T., Tanaka S. Early diagnosis of acute renal allograft rejection: efficacy of macrophage migration inhibition test as an immunological diagnosis. Acta Medica Okayama 1977, 31:177-186.
107. Bacher M., Meinhardt A., Lan H.Y., Mu W., Metz C.N., Chesney J.A., et al. Migration inhibitory factor expression in experimentally induced endotoxemia. American Journal of Pathology 1997, 150:235-246.
108. Hoi A.Y., Hickey M.J., Hall P., Yamana J., O'Sullivan K.M., Santos L.L., et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. Journal of Immunology 2006, 177:5687-5696.
109. Rice E.K., Nikolic-Paterson D.J., David J.R., Bucala R., Metz C.N., Atkins R.C., et al. Macrophage accumulation and renal fibrosis are independent of macrophage migration inhibitory factor in mouse obstructive nephropathy. Nephrology (Carlton) 2004, 9:278-287.
110. Kim Y.G., Huang X.R., Suga S., Mazzali M., Tang D., Metz C., et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Molecular Medicine 2000, 6:837-848.
111. Brown F.G., Nikolic-Paterson D.J., Metz C., Bucala R., Atkins R.C., Lan H.Y. Up-regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat. Clinical & Experimental Immunology 1999, 118:329-336.
112. Hattori M., Nikolic-Paterson D.J., Miyazaki K., Isbel N.M., Lan H.Y., Atkins R.C., et al. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney International Supplement 1999, 71:S47-S50.
113. Miyazaki K., Isbel N.M., Lan H.Y., Hattori M., Ito K., Bacher M., et al. Up-regulation of macrophage colony-stimulating factor (M-CSF) and migration inhibitory factor (MIF) expression and monocyte recruitment during lipid-induced glomerular injury in the exogenous hypercholesterolaemic (ExHC) rat. Clinical & Experimental Immunology 1997, 108:318-323.
114. Brown F.G., Nikolic-Paterson D.J., Chadban S.J., Dowling J., Jose M., Metz C.N., et al. Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection. Transplantation 2001, 71:1777-1783.
115. Matsumoto K., Kanmatsuse K. Increased production of macrophage migration inhibitory factor by T cells in patients with IgA nephropathy. American Journal of Nephrology 2001, 21:455-464.
116. Kuusniemi A.M., Lapatto R., Holmberg C., Karikoski R., Rapola J., Jalanko H. Kidneys with heavy proteinuria show fibrosis, inflammation, and oxidative stress, but no tubular phenotypic change. Kidney International 2005, 68:121-132.
117. Brown F.G., Nikolic-Paterson D.J., Hill P.A., Isbel N.M., Dowling J., Metz C.M., et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. Journal of the American Society of Nephrology 2002, 13(Suppl. 1):S7-S13.
118. Matsumoto K., Maruyama N., Maruyama T., Ohnishi Y., Nonaka S., Inoshita A., et al. Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis. Clinical & Experimental Immunology 2005, 139:338-347.
119. Bruchfeld A., Carrero J.J., Qureshi A.R., Lindholm B., Barany P., Heimburger O., et al. Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. Molecular Medicine 2009, 15:70-75.
120. Payen D., Lukaszewicz A.C., Legrand M., Gayat E., Faivre V., Megarbane B., et al. A multicentre study of acute kidney injury in severe sepsis and septic shock: association with inflammatory phenotype and HLA genotype. PLoS One 2012, 7:e35838.
121. Tripathi G., Borkar M., Akhter A., Sankhwar S.N., Sharma R.K., Agrawal S. Association of proinflammatory cytokines with end stage renal disease. Cytokine 2010, 50:278-283.
122. Du W., Wright B.M., Li X., Finke J., Rini B.I., Zhou M., et al. Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma. Oncogene 2012.
123. Bozza M., Satoskar A.R., Lin G., Lu B., Humbles A.A., Gerard C., et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. Journal of Experimental Medicine 1999, 189:341-346.
124. Mount P.F., Gleich K., Tam S., Fraser S.A., Choy S.W., Dwyer K.M., et al. The outcome of renal ischemia-reperfusion injury is unchanged in AMPK-beta1 deficient mice. PLoS One 2012, 7:e29887.
125. Yang N., Nikolic-Paterson D.J., Ng Y.Y., Mu W., Metz C., Bacher M., et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Molecular Medicine 1998, 4:413-424.
126. Jose M.D., David J.R., Atkins R.C., Chadban S.J. Blockade of macrophage migration inhibitory factor does not prevent acute renal allograft rejection. American Journal of Transplantation 2003, 3:1099-1106.
127. Ouertatani-Sakouhi H., El-Turk F., Fauvet B., Cho M.K., Pinar K.D., Le R.D., et al. Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. Journal of Biological Chemistry 2010, 285:26581-26598.
128. Al-Abed Y., Dabideen D., Aljabari B., Valster A., Messmer D., Ochani M., et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. Journal of Biological Chemistry 2005, 280:36541-36544.
129. Leng L., Chen L., Fan J., Greven D., Arjona A., Du X., et al. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. Journal of Immunology 2011, 186:527-538.
130. Cho Y., Crichlow G.V., Vermeire J.J., Leng L., Du X., Hodsdon M.E., et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proceedings of the National Academy of Sciences United States of America 2010, 107:11313-11318.
131. Jorgensen W.L., Trofimov A., Du X., Hare A.A., Leng L., Bucala R. Benzisothiazolones as modulators of macrophage migration inhibitory factor. Bioorganic & Medicinal Chemistry Letters 2011, 21:4545-4549.
132. Bai F., Asojo O.A., Cirillo P., Ciustea M., Ledizet M., Aristoff P.A., et al. A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF). Journal of Biological Chemistry 2012.
133. Borghese F., Clanchy F.I. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opinion on Therapeutic Targets 2011, 15:237-251.
134. Pyrz M., Wang B., Wabl M., Pedersen F.S. A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform. Molecular Cancer 2010, 9:86.
135. Arunachalam B., Lamb C.A., Cresswell P. Transport properties of free and MHC class II-associated oligomers containing different isoforms of human invariant chain. International Immunology 1994, 6:439-451.
136. Claesson L., Larhammar D., Rask L., Peterson P.A. cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure. Proceedings of the National Academy of Sciences United States of America 1983, 80:7395-7399.
137. Strubin M., Mach B., Long E.O. The complete sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity. EMBO Journal 1984, 3:869-872.
138. Warmerdam P.A., Long E.O., Roche P.A. Isoforms of the invariant chain regulate transport of MHC class II molecules to antigen processing compartments. Journal of Cell Biology 1996, 133:281-291.
139. Koch N., Lauer W., Habicht J., Dobberstein B. Primary structure of the gene for the murine Ia antigen-associated invariant chains (Ii). An alternatively spliced exon encodes a cysteine-rich domain highly homologous to a repetitive sequence of thyroglobulin. EMBO Journal 1987, 6:1677-1683.
140. Naujokas M.F., Morin M., Anderson M.S., Peterson M., Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993, 74:257-268.
141. Miller J., Hatch J.A., Simonis S., Cullen S.E. Identification of the glycosaminoglycan-attachment site of mouse invariant-chain proteoglycan core protein by site-directed mutagenesis. Proceedings of the National Academy of Sciences United States of America 1988, 85:1359-1363.
142. Roche P.A., Teletski C.L., Stang E., Bakke O., Long E.O. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proceedings of the National Academy of Sciences United States of America 1993, 90:8581-8585.
143. Matza D., Lantner F., Bogoch Y., Flaishon L., Hershkoviz R., Shachar I. Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. Proceedings of the National Academy of Sciences United States of America 2002, 99:3018-3023.
144. Leth-Larsen R., Lund R., Hansen H.V., Laenkholm A.V., Tarin D., Jensen O.N., et al. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Molecular & Cellular Proteomics 2009, 8:1436-1449.
145. Mellanby R.J., Koonce C.H., Monti A., Phillips J.M., Cooke A., Bikoff E.K. Loss of invariant chain protects nonobese diabetic mice against type 1 diabetes. Journal of Immunology 2006, 177:7588-7598.
146. Stumptner-Cuvelette P., Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochimica et Biophysica Acta 2002, 1542:1-13.
147. Lamb C.A., Cresswell P. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes. Journal of Immunology 1992, 148:3478-3482.
148. Roche P.A., Marks M.S., Cresswell P. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 1991, 354:392-394.
149. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annual Review of Immunology 1994, 12:259-293.
150. Huang D., Cai D.T., Chua R.Y., Kemeny D.M., Wong S.H. Nitric-oxide synthase 2 interacts with CD74 and inhibits its cleavage by caspase during dendritic cell development. Journal of Biological Chemistry 2008, 283:1713-1722.
151. Ogrinc T., Dolenc I., Ritonja A., Turk V. Purification of the complex of cathepsin L and the MHC class II-associated invariant chain fragment from human kidney. FEBS Letters 1993, 336:555-559.
152. Fiebiger E., Maehr R., Villadangos J., Weber E., Erickson A., Bikoff E., et al. Invariant chain controls the activity of extracellular cathepsin L. Journal of Experimental Medicine 2002, 196:1263-1269.
153. Basha G., Omilusik K., Chavez-Steenbock A., Reinicke A.T., Lack N., Choi K.B., et al. A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nature Immunology 2012, 13:237-245.
154. Szaszak M., Chen H.D., Chen H.C., Baukal A., Hunyady L., Catt K.J. Identification of the invariant chain (CD74) as an angiotensin AGTR1-interacting protein. Journal of Endocrinology 2008, 199:165-176.
155. Liao H., Bucala R., Mitchell R.A. Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF). Journal of Biological Chemistry 2003, 278:76-81.
156. Mitchell R.A., Metz C.N., Peng T., Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. Journal of Biological Chemistry 1999, 274:18100-18106.
157. Shi X., Leng L., Wang T., Wang W., Du X., Li J., et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006, 25:595-606.
158. Lesley J., Hyman R., Kincade P.W. CD44 and its interaction with extracellular matrix. Advances in Immunology 1993, 54:271-335.
159. Taher T.E., Smit L., Griffioen A.W., Schilder-Tol E.J., Borst J., Pals S.T. Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes. Journal of Biological Chemistry 1996, 271:2863-2867.
160. Meyer-Siegler K.L., Leifheit E.C., Vera P.L. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 2004, 4:34.
161. Gore Y., Starlets D., Maharshak N., Becker-Herman S., Kaneyuki U., Leng L., et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. Journal of Biological Chemistry 2008, 283:2784-2792.
162. Verschuren L., Kooistra T., Bernhagen J., Voshol P.J., Ouwens D.M., van E.M., et al. MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circulation Research 2009, 105:99-107.
163. Miller E.J., Li J., Leng L., McDonald C., Atsumi T., Bucala R., et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008, 451:578-582.
164. Qi D., Hu X., Wu X., Merk M., Leng L., Bucala R., et al. Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. Journal of Clinical Investigation 2009, 119:3807-3816.
165. Binsky I., Haran M., Starlets D., Gore Y., Lantner F., Harpaz N., et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proceedings of the National Academy of Sciences United States of America 2007, 104:13408-13413.
166. Beswick E.J., Pinchuk I.V., Suarez G., Sierra J.C., Reyes V.E. Helicobacter pylori CagA-dependent macrophage migration inhibitory factor produced by gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. Journal of Immunology 2006, 176:6794-6801.
167. Tarnowski M., Grymula K., Liu R., Tarnowska J., Drukala J., Ratajczak J., et al. Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Molecular Cancer Research 2010, 8:1328-1343.
168. Schwartz V., Lue H., Kraemer S., Korbiel J., Krohn R., Ohl K., et al. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Letters 2009, 583:2749-2757.
169. Lue H., Dewor M., Leng L., Bucala R., Bernhagen J. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signaling 2011, 23:135-144.
170. Lorz C., Benito-Martin A., Boucherot A., Ucero A.C., Rastaldi M.P., Henger A., et al. The death ligand TRAIL in diabetic nephropathy. Journal of the American Society of Nephrology 2008, 19:904-914.
171. Xin D., Rendon B.E., Zhao M., Winner M., McGhee C.A., Mitchell R.A., The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through beta-catenin-dependent and -independent mechanisms. Molecular Cancer Research 2010, 8:1601-1609.
172. Coleman A.M., Rendon B.E., Zhao M., Qian M.W., Bucala R., Xin D., et al. Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. Journal of Immunology 2008, 181:2330-2337.
173. Beswick E.J., Pinchuk I.V., Minch K., Suarez G., Sierra J.C., Yamaoka Y., et al. The Helicobacter pylori urease B subunit binds to CD74 on gastric epithelial cells and induces NF-kappaB activation and interleukin-8 production. Infection and Immunity 2006, 74:1148-1155.
174. Matza D., Kerem A., Medvedovsky H., Lantner F., Shachar I. Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain. Immunity 2002, 17:549-560.
175. Becker-Herman S., Arie G., Medvedovsky H., Kerem A., Shachar I. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Molecular Biology of the Cell 2005, 16:5061-5069.
176. Martin-Ventura J.L., Madrigal-Matute J., Munoz-Garcia B., Blanco-Colio L.M., Van O.M., Zalba G., et al. Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovascular Research 2009, 83:586-594.
177. Momburg F., Koch N., Moller P., Moldenhauer G., Butcher G.W., Hammerling G.J. Differential expression of Ia and Ia-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma. Journal of Immunology 1986, 136:940-948.
178. Badve S., Deshpande C., Hua Z., Logdberg L. Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class II antigens in the human fetus. Journal of Histochemistry and Cytochemistry 2002, 50:473-482.
179. Beswick E.J., Das S., Pinchuk I.V., Adegboyega P., Suarez G., Yamaoka Y., et al. Helicobacter pylori-induced IL-8 production by gastric epithelial cells up-regulates CD74 expression. Journal of Immunology 2005, 175:171-176.
180. Lawrance I.C., Fiocchi C., Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Human Molecular Genetics 2001, 10:445-456.
181. Bryan K.J., Zhu X., Harris P.L., Perry G., Castellani R.J., Smith M.A., et al. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Molecular Neurodegeneration 2008, 3:13.
182. Burton J.D., Ely S., Reddy P.K., Stein R., Gold D.V., Cardillo T.M., et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clinical Cancer Research 2004, 10:6606-6611.
183. Cuthbert R.J., Wilson J.M., Scott N., Coletta P.L., Hull M.A. Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. European Journal of Cancer 2009, 45:1654-1663.
184. Ioachim H.L., Pambuccian S.E., Hekimgil M., Giancotti F.R., Dorsett B.H. Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. American Journal Surgical Pathology 1996, 20:64-71.
185. Porter D., Lahti-Domenici J., Keshaviah A., Bae Y.K., Argani P., Marks J., et al. Molecular markers in ductal carcinoma in situ of the breast. Molecular Cancer Research 2003, 1:362-375.
186. Tamori Y., Tan X., Nakagawa K., Takai E., Akagi J., Kageshita T., et al. Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma. Oncology Reports 2005, 14:873-877.
187. Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Iwashige H., Aridome K., et al. Invariant chain expression in gastric cancer. Cancer Letters 2001, 168:87-91.
188. Koide N., Yamada T., Shibata R., Mori T., Fukuma M., Yamazaki K., et al. Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clinical Cancer Research 2006, 12:2419-2426.
189. Datta M.W., Shahsafaei A., Nadler L.M., Freeman G.J., Dorfman D.M. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Applied Immunohistochemistry Molecular Morphology 2000, 8:210-215.
190. Lazova R., Moynes R., May D., Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer 1997, 79:2115-2124.
191. Young A.N., Amin M.B., Moreno C.S., Lim S.D., Cohen C., Petros J.A., et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. American Journal of Pathology 2001, 158:1639-1651.
192. Sanchez-Nino M.D., Sanz A.B., Carrasco S., Saleem M.A., Mathieson P.W., Valdivielso J.M., et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrology Dialysis Transplantation 2011, 26:1797-1802.
193. Saleem M., Sawyer G.J., Schofield R.A., Seymour N.D., Gustafsson K., Fabre J.W. Discordant expression of major histocompatibility complex class II antigens and invariant chain in interstitial dendritic cells. Implications for self-tolerance and immunity. Transplantation 1997, 63:1134-1138.
194. Lapter S., Ben-David H., Sharabi A., Zinger H., Telerman A., Gordin M., et al. A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide. Immunology 2011, 132:87-95.
195. Bonsib S.M. Renal cystic diseases and renal neoplasms: a mini-review. Clinical Journal of the American Society of Nephrology 2009, 4:1998-2007.
196. Stein R., Mattes M.J., Cardillo T.M., Hansen H.J., Chang C.H., Burton J., et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clinical Cancer Research 2007, 13:5556s-5563s.
197. Stein R., Qu Z., Cardillo T.M., Chen S., Rosario A., Horak I.D., et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004, 104:3705-3711.
198. Griffiths G.L., Govindan S.V., Sgouros G., Ong G.L., Goldenberg D.M., Mattes M.J. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. International Journal of Cancer 1999, 81:985-992.
199. Govindan S.V., Goldenberg D.M., Elsamra S.E., Griffiths G.L., Ong G.L., Brechbiel M.W., et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. Journal of Nuclear Medicine 2000, 41:2089-2097.
200. Sapra P., Stein R., Pickett J., Qu Z., Govindan S.V., Cardillo T.M., et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clinical Cancer Research 2005, 11:5257-5264.
201. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nature Reviews Cancer 2011, 11:254-267.
202. Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS Journal 2011, 278:1429-1443.
203. Nikolic-Paterson D.J., Jun Z., Tesch G.H., Lan H.Y., Foti R., Atkins R.C. De novo CD44 expression by proliferating mesangial cells in rat anti-Thy-1 nephritis. Journal of the American Society of Nephrology 1996, 7:1006-1014.
204. Smeets B., Uhlig S., Fuss A., Mooren F., Wetzels J.F., Floege J., et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. Journal of the American Society of Nephrology 2009, 20:2604-2615.
205. Florquin S., Nunziata R., Claessen N., van den Berg F.M., Pals S.T., Weening J.J. CD44 expression in IgA nephropathy. American Journal of Kidney Diseases 2002, 39:407-414.
206. Rouschop K.M., Claessen N., Pals S.T., Weening J.J., Florquin S. CD44 disruption prevents degeneration of the capillary network in obstructive nephropathy via reduction of TGF-beta1-induced apoptosis. Journal of the American Society of Nephrology 2006, 17:746-753.
207. Yang L., Brozovic S., Xu J., Long Y., Kralik P.M., Waigel S., et al. Inflammatory gene expression in OVE26 diabetic kidney during the development of nephropathy. Nephron Experimental Nephrology 2011, 119:e8-e20.
208. Okada A., Yasui T., Fujii Y., Niimi K., Hamamoto S., Hirose M., et al. Renal macrophage migration and crystal phagocytosis via inflammatory-related gene expression during kidney stone formation and elimination in mice: detection by association analysis of stone-related gene expression and microstructural observation. Journal of Bone and Mineral Research 2010, 25:2701-2711.
209. Han D.H., Song H.K., Lee S.Y., Song J.H., Piao S.G., Yoon H.E., et al. Upregulation of hyaluronan and its binding receptors in an experimental model of chronic cyclosporine nephropathy. Nephrology (Carlton) 2010, 15:216-224.
210. Kocak B., Orug T., Turhan N., Ozcay N., Gonenc F. CD44 expression in renal ischemia-reperfusion injury in rats. International Urology and Nephrology 2009, 41:791-794.
211. Sicking E.M., Fuss A., Uhlig S., Jirak P., Dijkman H., Wetzels J., et al. Subtotal ablation of parietal epithelial cells induces crescent formation. Journal of the American Society of Nephrology 2012, 23:629-640.
212. Herrera M.B., Bussolati B., Bruno S., Morando L., Mauriello-Romanazzi G., Sanavio F., et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney International 2007, 72:430-441.
213. Takazoe K., Tesch G.H., Hill P.A., Hurst L.A., Jun Z., Lan H.Y., et al. CD44-mediated neutrophil apoptosis in the rat. Kidney International 2000, 58:1920-1930.
214. Burger J.A., Kipps T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767.
215. Schodel J., Bohr D., Klanke B., Schley G., Schlotzer-Schrehardt U., Warnecke C., et al. Factor inhibiting HIF limits the expression of hypoxia-inducible genes in podocytes and distal tubular cells. Kidney International 2010, 78:857-867.
216. Ray P.E., Soler-Garcia A.A., Xu L., Soderland C., Blumenthal R., Puri A. Fusion of HIV-1 envelope-expressing cells to human glomerular endothelial cells through an CXCR4-mediated mechanism. Pediatric Nephrology 2005, 20:1401-1409.
217. Hatsukari I., Singh P., Hitosugi N., Messmer D., Valderrama E., Teichberg S., et al. DEC-205-mediated internalization of HIV-1 results in the establishment of silent infection in renal tubular cells. Journal of the American Society of Nephrology 2007, 18:780-787.
218. Ding M., Cui S., Li C., Jothy S., Haase V., Steer B.M., et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nature Medicine 2006, 12:1081-1087.
219. Cook H.T., Tarzi R., D'Souza Z., Laurent G., Lin W.C., Aitman T.J., et al. AP-1 transcription factor JunD confers protection from accelerated nephrotoxic nephritis and control podocyte-specific Vegfa expression. American Journal of Pathology 2011, 179:134-140.
220. Wang A., Fairhurst A.M., Tus K., Subramanian S., Liu Y., Lin F., et al. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. Journal of Immunology 2009, 182:4448-4458.
221. Gemmill R.M., Bemis L.T., Lee J.P., Sozen M.A., Baron A., Zeng C., et al. The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. Oncogene 2002, 21:3507-3516.
222. Neusser M.A., Lindenmeyer M.T., Moll A.G., Segerer S., Edenhofer I., Sen K., et al. Human nephrosclerosis triggers a hypoxia-related glomerulopathy. American Journal of Pathology 2010, 176:594-607.
223. Chu P.Y., Zatta A., Kiriazis H., Chin-Dusting J., Du X.J., Marshall T., et al. CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circulation: Heart Failure 2011, 4:651-658.
224. Park H.C., Yasuda K., Ratliff B., Stoessel A., Sharkovska Y., Yamamoto I., et al. Postobstructive regeneration of kidney is derailed when surge in renal stem cells during course of unilateral ureteral obstruction is halted. American Journal of Physiology-Renal Physiology 2010, 298:F357-F364.
225. Takabatake Y., Sugiyama T., Kohara H., Matsusaka T., Kurihara H., Koni P.A., et al. The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. Journal of the American Society of Nephrology 2009, 20:1714-1723.
226. Petruzziello-Pellegrini T.N., Yuen D.A., Page A.V., Patel S., Soltyk A.M., Matouk C.C., et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. Journal of Clinical Investigation 2012, 122:759-776.
227. D'Alterio C., Consales C., Polimeno M., Franco R., Cindolo L., Portella L., et al. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Current Cancer Drug Targets 2010, 10:772-781.
228. D'Alterio C., Cindolo L., Portella L., Polimeno M., Consales C., Riccio A., et al. Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 2010, 9:4492-4500.
229. Li L., Huang L., Vergis A.L., Ye H., Bajwa A., Narayan V., et al. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. Journal of Clinical Investigation 2010, 120:331-342.
230. Svensson M., Irjala H., Svanborg C., Godaly G. Effects of epithelial and neutrophil CXCR2 on innate immunity and resistance to kidney infection. Kidney International 2008, 74:81-90.
231. Cugini D., Azzollini N., Gagliardini E., Cassis P., Bertini R., Colotta F., et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney International 2005, 67:1753-1761.
232. Ueland J.M., Gwira J., Liu Z.X., Cantley L.G. The chemokine KC regulates HGF-stimulated epithelial cell morphogenesis. American Journal of Physiology-Renal Physiology 2004, 286:F581-F589.
233. Togel F., Isaac J., Hu Z., Weiss K., Westenfelder C. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney International 2005, 67:1772-1784.
234. Mazzinghi B., Ronconi E., Lazzeri E., Sagrinati C., Ballerini L., Angelotti M.L., et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. Journal of Experimental Medicine 2008, 205:479-490.